-
BeiGene will present its Hematology Oncology Clinical Development Program Update at the 64th American Society of Hematology Annual Meeting
Time of Update: 2022-11-14
About BRUKINSA ® BRUKINSA ® (zebrutinib) is a Bruton's tyrosine kinase (BTK) small molecule inhibitor independently developed by BeiGene scientists and is currently undergoing extensive clinical trials worldwide as a monotherapy and in combination with other therapies for the treatment of a variety of B-cell malignancies.
-
Keyue Pharma announced the complete data of the phase I clinical trial SYNERGY-1 of KP104
Time of Update: 2022-11-14
Details of the presentation are below : SYNERGY-1: Phase I, first-in-human study evaluating the safety, tolerability, immunogenicity, and single- and multiple-dose escalation of KP104 for PK104 By Paul Wabinitz1, Xiang Gao2, Jay Ma2, Ping Tsui2, Martin Rabe2, Helen Fu2, Chaomei He2, Jingtao Wu2, Brian York2, Qing Yu Christina Weng 2,3, Jon Rankin4, Frederick Beddingfield 2,5, Wenru Song2、Nicholas Farinola1、Richard Lee2 Abstract number: 3761666 Session Name: Glomerular Disease: IgA and Complement-mediated Glomerulonephritis[PO1302-3] Conference date and time: November 5, 2022, 10:00 a.
-
At the 64th ASH Annual Meeting, we will present the clinical data of FasTCAR-T GC012F for the first time in patients with multiple myeloma
Time of Update: 2022-11-14
Global clinical-stage biopharmaceutical company Ganxi Biotechnology Group (NASDAQ: GRCL; On November 3, "Ganxi Biologics") announced the preliminary data of a Phase 1 clinical trial initiated by its investigators in China to evaluate the efficacy of its candidate GC012F based on the FasTCAR platform in the treatment of high-risk patients with multiple myeloma (NDMM) who are eligible for transplantation.
-
I-Mab will present two new results of lezolimab at the 2022 American Society of Hematology (ASH) Annual Meeting
Time of Update: 2022-11-14
Morial Convention Center, Hall D Date/Time: December 12, 2022, 6:00-8:00 PM EDT Abstract Overview: The combination therapy of lezorolimab and azacitidine can induce upregulation of calreticin expression in tumor cells, and the number of macrophages and CD8/Treg ratio in the bone marrow at baseline are positively correlated with clinical efficacy, suggesting that the activation of tumor pro-swallowing signals and the number of effector cells play an important role in the effect of combination therapy.
-
The latest research progress and prospect of PROTAC for non-enzymatic function of target proteins
Time of Update: 2022-11-14
Studies have shown that the non-enzymatic function of target proteins plays a key role in the regulation of multiple cell signaling pathways and is closely related to many human diseases.
-
Bristol-Myers Squibb debuted at the 5th CIIE with 12 global innovations
Time of Update: 2022-11-13
Shanghai, China, November 6, 2022 – On the occasion of its 40th anniversary in China, Bristol-Myers Squibb has returned to CIBO with the company's "China 2030 Strategy" with the theme of "'Protecting
-
This multinational pharmaceutical company is increasing its layout in the Chinese medicine market!
Time of Update: 2022-11-11
"hand in hand", the two sides will work together to build a highland of traditional Chinese medicine industry, in Chengdu high-tech zone to land a new type of R & D transformation institution, and Boji Pharmaceutical will provide AstraZeneca with a number of services such as traditional Chinese medicine research and development (including pharmaceutical research, non-clinical research, clinical research, registration services, etc.
-
Talent mobility in multinational pharmaceutical companies is accelerating, and former Novartis executives will join Boehringer Ingelheim
Time of Update: 2022-11-11
It is understood that the new CMO Lykke Hinsch Gylvin previously served at Novartis as vice president of global medical franchise and head of neuroscience.
It is understood that the new CMO Lykke Hinsch Gylvin previously served at Novartis as vice president of global medical franchise and head of neuroscience.
-
Pharmaceutical companies keen on "buying, buying and buying" announced the termination of a large acquisition of more than 1 billion yuan!
Time of Update: 2022-11-11
Fosun Pharma has started the road of investment and mergers and acquisitions as early as its landing on the A-share main board market, including many overseas companies such as Alma, a global medical cosmetology company.
-
The ophthalmic medical company invested 464 million yuan in two industrial fund companies
Time of Update: 2022-11-11
The fund size of Hefei Infineon Health Technology Venture Capital Partnership (Limited Partnership) is 1 billion yuan, of which OPPLE Investment subscribed 349 million yuan, with a capital contribution ratio of 34.
-
The Phase I clinical trial of PIONEER PHARMACEUTICAL'S AR-PROTAC (GT20029) completed the enrollment of subjects for dosing
Time of Update: 2022-11-04
HK), a biopharmaceutical company focused on the development and industrialization of potential first-in-class and best-in-class innovative drugs, announced on October 27 that its self-developed novel protein-degrading chimera (PROTAC) compound GT20029 targeting androgen receptors (AR) in the US phase I clinical trial for the treatment of androgenetic alopecia and acne has completed the enrollment and administration of all 120 subjects on October 25, 2022.
-
Tengsheng Bo Pharma announced the top-line results of a Phase 1 study of BRII-296, a long-acting therapy for postpartum depression
Time of Update: 2022-11-04
HK), a multinational company dedicated to developing innovative therapies for unmet patient needs and major public health diseases, announced on September 26 that it is developing top-line results from a Phase 1 study of BRII-296, a long-acting single-shot therapy for the treatment of postnatal depression (PPD).
-
East Sunshine Medicine has 33 Class 1 new drugs dominating the screen, and 42 varieties have been evaluated
Time of Update: 2022-11-04
Recently, East Sunshine Pharmaceutical's product line has been dynamic: Class 1 new drug HEC138671 tablets have been approved for clinical trials, insulin aspart injection has been approved for marketing, and the first generic patent challenge of fingolimod capsules has been successful.
-
The application for clinical trial of Rico's new adjuvant recombinant quadrivalent HPV epidemic in China was accepted
Time of Update: 2022-11-04
js?cdnversion='+~(-new Date()/36e5)];On October 27, Jiangsu Ruike Biotechnology Co.
js?cdnversion='+~(-new Date()/36e5)];On October 27, Jiangsu Ruike Biotechnology Co.
js?cdnversion='+~(-new Date()/36e5)];On October 27, Jiangsu Ruike Biotechnology Co.
js?cdnversion='+~(-new Date()/36e5)];On October 27, Jiangsu Ruike Biotechnology Co.
-
Remegen announced the data of a domestic phase II clinical study for the treatment of myasthenia gravis
Time of Update: 2022-11-04
Currently, Remegen is actively conducting phase II or III clinical studies of tetacept for the treatment of autoimmune diseases in a variety of other indications to address the large unmet medical needs in this therapeutic area.
-
CANbridge announces positive top-line data from Maralixibat/LIVMALLI in a Phase 3 trial for the treatment of progressive familial intrahepatic cholestasis
Time of Update: 2022-11-04
CANbridge has an exclusive license to develop and commercialize maralixibat (CAN108) in Greater China for the treatment of three rare liver diseases, including biliary atresia (BA), Arajeri syndrome (ALGS) and PFIC.
-
Continuing to innovate the main business of traditional Chinese medicine, the net profit of this pharmaceutical company increased by nearly 900% year-on-year
Time of Update: 2022-11-04
【Pharmaceutical Network Enterprise News】Fangsheng Pharmaceutical released the third quarterly report of 2022 on the evening of October 30, and the company's operating income in the reporting period wa
-
InnoCare completed the administration of the first adolescent patient with the second-generation pan-TRK inhibitor ICP-723
Time of Update: 2022-11-04
On October 31, 2022, InnoCare (SSE: 688428; HKEx: 09969) today announced that the company's self-developed second-generation pan-TRK small molecule inhibitor ICP-723 has completed the first dose in adolescent patients in the Department of Pediatric Oncology, Sun Yat-sen University Cancer Prevention and Treatment Center, which is also the first clinical study of ICP-723 in adolescent (12 to 18 years old) patients after showing good safety and efficacy in adult patients.
-
First, positive interim analysis results were obtained for the phase 2b clinical trial of up to XW003 (Ecnoglutide) obesity
Time of Update: 2022-11-04
, a clinical-stage biotechnology company focused on the research and development of innovative therapies for the treatment of chronic metabolic diseases, today announced the positive interim analysis results of its ongoing Phase 2b clinical trial of XW003 (Ecnoglutide) obesity.
-
Not to be underestimated! Eritative history of hydrogels and drug delivery
Time of Update: 2022-11-04
Hydrogels are composed of hydrophilic polymers, and their three-dimensional network structure can not only absorb a large amount of water, but also can be used to carry drugs Hydrogels prepared with
